Guangdong Zhongsheng Pharmaceutical Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St · 08/30 22:56

Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥723.2m (down 1.7% from 2Q 2023).
  • Net income: CN¥36.1m (down 48% from 2Q 2023).
  • Profit margin: 5.0% (down from 9.4% in 2Q 2023).
  • EPS: CN¥0.04 (down from CN¥0.088 in 2Q 2023).
earnings-and-revenue-growth
SZSE:002317 Earnings and Revenue Growth August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Guangdong Zhongsheng Pharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 71%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 3.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Guangdong Zhongsheng Pharmaceutical has 3 warning signs (and 1 which can't be ignored) we think you should know about.